BioWorld Science

Oct. 19, 2020

View Archived Issues

Bromodomain 2-selective BET inhibitors show antitumor effect in pediatric cancer models

Read More

Medicenna outlines phase III plans for MDNA-55 in recurrent glioblastoma

Read More

NIAID initiates phase I study of SAR-440894

Read More

Avalyn advances phase I/II study of AP-101 in IPF

Read More

Recce receives ethics approval to initiate phase I/II burn wound study of RECCE-327

Read More

CKD-508, second-generation CETP inhibitor with improved safety and efficacy

Read More

Medshine Discovery patents Ret inhibitors

Read More

Neutrophils are literal obstacle to stroke recovery

Read More

Albumin transports proteins across mucosa, into lymph nodes

Read More

Insilico Medicine discloses JAK inhibitors

Read More

Epizyme presents CREBBP and KAT3B inhibitors

Read More

FZD6 as novel biomarker of depression

Read More

Ventyx Biosciences discloses TYK2 ligands

Read More

WHO Solidarity interim results show repurposed antivirals for COVID-19 have little or no effect

Read More

Baylor College of Medicine identifies new antiviral compounds

Read More

TRPA1 channel as a new therapeutic target for chronic post-thoracotomy pain

Read More

New model created for CFTR gene nonsense mutation W1282X cystic fibrosis

Read More

Cellular "pantry" of sorts, lipid droplets double as home security system

Read More

Snai1 inhibition may ameliorate right ventricular failure due to pulmonary hypertension

Read More

Furin inhibitor BOS-318 seems effective for treating cystic fibrosis

Read More

PharmaMar reports data from APLICOV-PC trial with Aplidin in COVID-19

Read More

Agios withdraws MAA for Tibsovo for relapsed or refractory AML with IDH1 mutation

Read More

Orion's OB-002H for prevention of HIV completes first-in-human study

Read More

Aptose begins phase Ia/b study of CG-806 in AML

Read More

FDA clears Mereo to begin phase Ib/II basket study of etigilimab

Read More